Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 January 2007, Vol. 109, No. 2, pp. 610-612.
Prepublished online as a Blood First Edition Paper on September 19, 2006; DOI 10.1182/blood-2006-05-022756.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2006-05-022756v1
109/2/610    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dasgupta, S.
Right arrow Articles by Lacroix-Desmazes, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dasgupta, S.
Right arrow Articles by Lacroix-Desmazes, S.
Related Collections
Right arrow Brief Reports
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY

Brief report

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors

Suryasarathi Dasgupta1,2, Yohann Repessé1,3, Jagadeesh Bayry1,2, Ana-Maria Navarrete1,2, Bharath Wootla1,2, Sandrine Delignat1,2, Theano Irinopoulou2,4, Caroline Kamaté5, Jean-Marie Saint-Remy6, Marc Jacquemin6, Peter J. Lenting5, Annie Borel-Derlon3, Srinivas V. Kaveri1,2, and Sébastien Lacroix-Desmazes1,2,

1 Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U) 681, Paris, France; 2 Université Pierre et Marie Curie–Paris 6, Institut des Cordeliers, Institut Fédératif de Recherche (IFR) 58, and Institut du Fer a Moulin, IFR 83, Paris, France; 3 Université de Caen, Laboratoire d'hématologie Equipe d'Accueil (EA) 3212, Caen, France; 4 INSERM, U536, U706, Paris, France; 5 Laboratory for Thrombosis and Haemostasis, Department of Hematology, University Medical Center, Utrecht, The Netherlands; 6 Center for Molecular and Vascular Biology, University of Leuven, Belgium

Von Willebrand factor (VWF) is a chaperone molecule for procoagulant factor VIII (FVIII). Its role in the reduction of the immunogenicity of therapeutic FVIII in patients with hemophilia A has been evoked but lacks clear cellular and molecular rationale. Here, we demonstrate that VWF protects FVIII from being endocytosed by human dendritic cells (DCs) and subsequently presented to FVIII-specific T cells. The immunoprotective effect of VWF requires a physical interaction with FVIII because the endocytosis of FVIII was significantly restored on hindering the formation of the VWF-FVIII complex. Interestingly, VWF had no direct inhibitory effect either on the ability of DCs to present antigenic peptides or on the activation potency of CD4+ T cells. We thus propose that VWF may reduce the immunogenicity of FVIII by preventing, upstream from the activation of immune effectors, the entry of FVIII in professional antigen-presenting cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
S. Dasgupta, A. M. Navarrete, S. Andre, B. Wootla, S. Delignat, Y. Repesse, J. Bayry, A. Nicoletti, E. L. Saenko, R. d'Oiron, et al.
Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation
Haematologica, January 1, 2008; 93(1): 83 - 89.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
S. Delignat, S. Dasgupta, S. Andre, A.-M. Navarrete, S. V. Kaveri, J. Bayry, M.-H. Andre, S. Chtourou, Z. Tellier, and S. Lacroix-Desmazes
Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A
Haematologica, October 1, 2007; 92(10): 1423 - 1426.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Calvez, Y. Laurian, and J. Goudemand
Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis
Blood, August 1, 2007; 110(3): 1073 - 1074.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Dasgupta, A.-M. Navarrete, J. Bayry, S. Delignat, B. Wootla, S. Andre, O. Christophe, M. Nascimbeni, M. Jacquemin, L. Martinez-Pomares, et al.
A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes
PNAS, May 22, 2007; 104(21): 8965 - 8970.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020